APTA Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies for diseases associated with regulatory autoantibodies, strengthens its management team.

Click here for the article:

https://thesicktimes.org/2025/07/22/berlin-cures-failed-long-covid-clinical-trial-yields-lessons-on-study-design/

The newly founded APTA Therapeutics has acquired assets from Berlin Cures and intends to continue clinical development of rovunaptabin, formally BC 007.